2-乙基-5-苯基-噻唑 | 19968-74-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-乙基-5-苯基-噻唑
• 英文名称: 2-Ethyl-5-phenyl-thiazol
• 英文别名: 2-ethyl-5-phenyl-thiazole；2-Ethyl-5-phenyl-1,3-thiazole
• CAS: 19968-74-2
• 化学式: C₁₁H₁₁NS
• 分子量: 189.281
• InChiKey: UXODLPWQMZPFOA-UHFFFAOYSA-N

物化性质

• 熔点：
  81 °C
• 沸点：
  307.7±11.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-乙基噻唑 、 过氧化苯甲酰 反应 20.0h， 生成 2-Ethyl-4-phenyl-thiazol 、 2-乙基-5-苯基-噻唑
  参考文献：
  名称：

  Vernin,G. et al., Bulletin de la Societe Chimique de France, 1967, p. 4514 - 4520

  摘要：

  DOI：

文献信息

• Histone Deacetylase Inhibitors
  申请人：Moffat David Festus Charles

  公开号：US20100152155A1

  公开（公告）日：2010-06-17

  Compounds of formula: (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: (I) wherein Q, V and W independently represent —N═ or —C═; B is a divalent radical selected from: (IIA), (IIB), (IIC), (IID), and (IIE). Wherein the bond marked * is linked to the ring containing Q, V and W through -[Linker1]- and the bond marked ** is linked to A through -[Linker2]-; A is an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; and -[Linker1]- and -[Linker2]- independently represent a bond, or a divalent linker radical.

  式为(I)的化合物、盐、N-氧化物、水合物和溶剂化物均为组蛋白去乙酰化酶抑制剂，可用于治疗细胞增殖性疾病，包括癌症：(I)其中Q、V和W分别代表—N═或—C═；B是从(IIA)、(IIB)、(IIC)、(IID)和(IIE)中选择的二价基团。其中标记为*的键通过-[连接1]-与含有Q、V和W的环相连，标记为**的键通过-[连接2]-与A相连；A是一个可选取代的单环、双环或三环碳环或杂环系统；-[连接1]-和-[连接2]-分别表示键或二价连接基团。
• Enzyme Inhibitors
  申请人：Davidson Alan Hornsby

  公开号：US20090291978A1

  公开（公告）日：2009-11-26

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, C(═O)—, —S(═O) 2 —, —C(—O)O—, —C(O)NR 3 —, —C(═S)—NR 3 , —C(═NH)NR 3 or —S(═O) 2 NR 3 — wherein R 3 is hydrogen or optionally substituted C 1 -C 6 alkyl; L is a divalent radical of formula -(Alk 1 ) m (O) n (Alk 2 ) p — wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X 2 -Q 1 - or -Q 1 -X 2 — wherein X 2 is —O—, S— or NR A — wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl, and Q 1 is an optionally substituted divalent mono- or bicyclic carbocyclic or hetero-cyclic radical having 5-13 ring members, AIk 1 and AIk 2 independently represent optionally substituted divalent C 3 -C 7 cycloalkyl radicals, or optionally substituted straight or branched, C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals which may optionally contain or terminate in an ether (—O—), thioether (—S—) or amino (—NR A -) link wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl; X represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —, —NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; z is 0 or 1; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R 1 R 2 NH—Y-L 1 -X 1 —[CH 2 ] z — and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONHOH, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.

  式(I)的化合物是组蛋白去乙酰化酶抑制剂，可用于治疗癌症等疾病，其中R1是羧酸基（-COOH）或一个可被一个或多个细胞内羧酸酯酶水解为羧酸基的酯基；R2是天然或非天然α氨基酸的侧链；Y是键，C（═O）—，—S（═O）2—，—C（—O）O—，—C（O）NR3—，—C（═S）—NR3，—C（═NH）NR3或—S（═O）2NR3—，其中R3是氢或可选择性取代的C1-C6烷基；L是式-(Alk1)m(O)n(Alk2)p-的二价基团，其中m、n和p分别独立为0或1；Q是（i）一个可选择性取代的二价单环或双环碳环或杂环基团，其具有5-13个环成员，或（ii）在m和p都为0的情况下，是式—X2-Q1-或-Q1-X2—的二价基团，其中X2是—O—，S—或NRA—，其中RA是氢或可选择性取代的C1-C3烷基，Q1是一个可选择性取代的二价单环或双环碳环或杂环基团，其具有5-13个环成员，Alk1和Alk2独立地表示可选择性取代的二价C3-C7环烷基基团，或可选择性取代的直链或支链C1-C6烷基、C2-C6烯基或C2-C6炔基基团，其可以选择性地包含或终止于醚（-O-）、硫醚（-S-）或氨基（-NRA-）链，其中RA是氢或可选择性取代的C1-C3烷基；X表示键，—C（═O）；或—S（═O）2—；—NR4C（═O）—，—C（═O）NR4—，—NR4C（═O）NR5—，—NR4S（═O）2—或—S（═O）2NR4—，其中R4和R5独立地为氢或可选择性取代的C1-C6烷基；z为0或1；A表示可选择性取代的单环、双环或三环碳环或杂环系统，其中基团R1R2NH—Y-L1-X1—[CH2]z—和HONHCO-[LINKER]-附着于不同的环原子上；-[Linker]-表示连接A中的一个环原子与羟酰胺酸基团CONHOH的二价连接基团，连接基团的长度，从连接到A环原子的末端原子到连接到羟酸胺基团的末端原子，相当于3-10个碳原子的直链饱和烃链的长度。
• HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY
  申请人：Davidson Alan Hornsby

  公开号：US20090298924A1

  公开（公告）日：2009-12-03

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers: wherein Y 1 is a bond, —(C═O)—, —S(O 2 )—, —C(═O)O—, —OC(═O)—, —(C═O)NR 3 —, —NR 3 (C═O)—, —S(O 2 )NR 3 —, —NR 3 S(O 2 )—, or —NR 3 (C═O)NR 5 —, wherein R 3 and R 5 are independently hydrogen or optionally substituted (C 1 -C 6 )alkyl, L 1 is a divalent radical of formula -(Alk 1 ) m (O) n (Alk 2 ) p — wherein m, n, p, Alk 1 , Alk 2 and Q are as defined in the claims; z is 0 or 1; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker]- represents a divalent linker radical; R is a radical of formula (X) or (Y): wherein R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R 4 is hydrogen; or optionally substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, aryl, aryl(C 1 -C 6 alkyl)-, heteroaryl, heteroaryl(C 1 -C 6 alkyl)-, —(C═O)R 3 , —(C═O)OR 3 , or —(C═O)NR 3 wherein R 3 is hydrogen or optionally substituted (C 1 -C 6 )alkyl, C 3 -C 7 cycloalkyl, aryl, aryl(C 1 -C 6 alkyl)-, heteroaryl, or heteroaryl(C 1 -C 6 alkyl)-; R 4 1 is hydrogen or optionally substituted C 1 -C 6 alkyl; and B is a monocyclic heterocyclic ring of 5 or 6 ring atoms wherein R 1 is linked to a ring carbon adjacent the ring nitrogen shown, and ring B is optionally fused to a second carbocyclic or heterocyclic ring of 5 or 6 ring atoms in which case the bond shown intersected by a wavy line may be from a ring atom in said second ring;

  式(I)的化合物是组蛋白去乙酰化酶活性的抑制剂，可用于治疗癌症等疾病：其中Y1是键，—(C═O)—、—S(O2)—、—C(═O)O—、—OC(═O)—、—(C═O)NR3—、—NR3(C═O)—、—S(O2)NR3—、—NR3S(O2)—或—NR3(C═O)NR5—，其中R3和R5分别是氢或可选取代的（C1-C6）烷基，L1是式-(Alk1)m(O)n(Alk2)p-的二价基团，其中m、n、p、Alk1、Alk2和Q如权利要求所定义；z为0或1；A代表可选取代的单环、双环或三环碳环或杂环系统；-[链接体]-代表二价的连接基团；R是式(X)或(Y)的基团：其中R1是羧酸基（—COOH），或可由一个或多个细胞内羧酸酯酶酶解为羧酸基的酯基；R4是氢；或可选取代的C1-C6烷基、C3-C7环烷基、芳基、芳基(C1-C6烷基)-、杂环芳基、杂环芳基(C1-C6烷基)-、—(C═O)R3、—(C═O)OR3或—(C═O)NR3，其中R3是氢或可选取代的（C1-C6）烷基、C3-C7环烷基、芳基、芳基(C1-C6烷基)-、杂环芳基或杂环芳基(C1-C6烷基)-；R41是氢或可选取代的C1-C6烷基；B是由5个或6个环原子组成的单环杂环，其中R1与所示的环氮相邻的环碳相连，并且环B可选择与第二个由5个或6个环原子组成的碳环或杂环融合，此时由波浪线相交的键可能来自于所述第二个环中的一个环原子。
• Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands
  申请人：Cook, II James H.

  公开号：US20120035178A1

  公开（公告）日：2012-02-09

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了I式化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是尼古丁酸α7受体的配体，可以用于治疗各种中枢神经系统的疾病，特别是情感和神经退行性疾病。
• PYRIDO[3,4-B]INDOLES AND METHODS OF USE
  申请人：Medivation Technologies, Inc.

  公开号：US20130190323A1

  公开（公告）日：2013-07-25

  This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的杂环化合物，可用于调节个体中的组胺受体。描述了吡啶并[3,4-b]吲哚，以及包含该化合物的药物组合物和使用该化合物治疗各种治疗应用程序的方法，包括治疗认知障碍，精神疾病，神经递质介导的疾病和/或神经元疾病。